Development of anticancer drugs based on the hallmarks of tumor cells

Please use this identifier to cite or link to this item: http://dspace.utpl.edu.ec/handle/123456789/19172

Full metadata record

DC Field	Value	Language
dc.contributor.author	Bailon Moscoso, N.	es_ES
dc.contributor.author	Romero Benavides, J.	es_ES
dc.date.accessioned	2017-06-16T22:03:04Z	-
dc.date.available	2017-06-16T22:03:04Z	-
dc.date.issued	2014-01-01	es_ES
dc.date.submitted	28/02/2014	es_ES
dc.identifier	10.1007/s13277-014-1649-y	es_ES
dc.identifier.isbn	10104283	es_ES
dc.identifier.other	10.1007/s13277-014-1649-y	es_ES
dc.identifier.uri	http://dspace.utpl.edu.ec/handle/123456789/19172	-
dc.description.abstract	Cancer remains a public health problem with a high unmet medical demand. However, in recent decades, the knowledge of several functional molecular and biological traits that distinguish tumor cells from normal cells, known as the hallmarks of cancer as described by Hannahan and Weinberg, has led to new and modern therapeutic approaches against this disease. Most cancer drugs are deliberately developed for specific molecular targets that involve these hallmarks. In this review, we address the currently available cancer drugs and development of new drugs from the perspective of their interaction with these hallmarks as well as the pathways and mechanisms involved. © 2014 International Society of Oncology and BioMarkers (ISOBM).	es_ES
dc.language	Inglés	es_ES
dc.subject	Cancer	es_ES
dc.subject	Cancer cell hallmarks	es_ES
dc.subject	Drug design	es_ES
dc.title	Development of anticancer drugs based on the hallmarks of tumor cells	es_ES
dc.type	Article	es_ES
dc.publisher	Tumor Biology	es_ES
Appears in Collections:	Artículos de revistas Científicas

Files in This Item: